Log in

Isoray Stock Forecast, Price & News

0.00 (0.00 %)
(As of 11/25/2020 12:00 AM ET)
Today's Range
Now: $0.36
50-Day Range N/A
52-Week Range
Now: $0.36
Volume1.08 million shs
Average Volume544,074 shs
Market Capitalization$31.65 million
P/E RatioN/A
Dividend YieldN/A
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
Read More
Isoray logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars

Industry, Sector and Symbol

Industry Medical Instruments & Supplies
Previous SymbolNYSEMKT:ISR
Phone(509) 375-1202



Sales & Book Value

Annual SalesN/A



Market Cap$31.65 million
Next Earnings Date2/9/2021 (Estimated)
OptionableNot Optionable
0.00 (0.00 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for ISR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Isoray (NYSEAMERICAN:ISR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Isoray?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Isoray

What stocks does MarketBeat like better than Isoray?

Wall Street analysts have given Isoray a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Isoray wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Isoray's next earnings date?

Isoray is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for Isoray

How were Isoray's earnings last quarter?

Isoray, Inc. (NYSEAMERICAN:ISR) announced its quarterly earnings results on Tuesday, November, 10th. The healthcare company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01).
View Isoray's earnings history

What guidance has Isoray issued on next quarter's earnings?

Isoray updated its first quarter 2021 After-Hours earnings guidance on Thursday, September, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.3-2.5 million, compared to the consensus revenue estimate of $3.1 million.

What price target have analysts set for ISR?

3 brokerages have issued 1 year price targets for Isoray's stock. Their forecasts range from $1.25 to $1.75. On average, they expect Isoray's share price to reach $1.50 in the next year. This suggests a possible upside of 313.3% from the stock's current price.
View analysts' price targets for Isoray

Are investors shorting Isoray?

Isoray saw a drop in short interest in the month of October. As of October 30th, there was short interest totaling 962,400 shares, a drop of 25.4% from the October 15th total of 1,290,000 shares. Based on an average trading volume of 570,200 shares, the days-to-cover ratio is presently 1.7 days.
View Isoray's Short Interest

Who are some of Isoray's key competitors?

What other stocks do shareholders of Isoray own?

Who are Isoray's key executives?

Isoray's management team includes the following people:
  • Lori A. Woods, Chief Executive Officer & Director
  • Jennifer Streeter, Chief Operating Officer & VP-Human Resources
  • Mark J. Austin, Co-CFO, Secretary & Chief Accounting Officer
  • Jonathan R. Hunt, Co-Chief Financial Officer
  • William A. Cavanagh, Chief Research & Development Officer

What is Isoray's stock symbol?

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Who are Isoray's major shareholders?

Isoray's stock is owned by a variety of retail and institutional investors. Top institutional investors include Squarepoint Ops LLC (0.10%) and Avantax Advisory Services Inc. (0.07%). Company insiders that own Isoray stock include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh.
View institutional ownership trends for Isoray

Which major investors are buying Isoray stock?

ISR stock was acquired by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, and Avantax Advisory Services Inc.. Company insiders that have bought Isoray stock in the last two years include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale, and William Cavanagh.
View insider buying and selling activity for Isoray

How do I buy shares of Isoray?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Isoray's stock price today?

One share of ISR stock can currently be purchased for approximately $0.36.

How big of a company is Isoray?

Isoray has a market capitalization of $31.65 million. Isoray employs 53 workers across the globe.

What is Isoray's official website?

The official website for Isoray is isoray.com.

How can I contact Isoray?

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at (509) 375-1202.

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.